RA CAPITAL MANAGEMENT, L.P. purchased $194K of ARTV (indirect holdings)
RA CAPITAL MANAGEMENT, L.P. purchased 21,654 indirectly-held shares of Artiva Biotherapeutics, Inc. (ARTV) at an average of $8.96 ($8.94–$8.97, $0.19M total) across 2 trades over 2026-07-10 to 2026-07-13.
How this was made
The 30-second read
Why it matters
The newest fact is the reported open-market purchase by RA Capital Management, L.P. (director and 10% owner) at an average price of $8.9609, totaling $194,039.82, with holdings after the transaction of 16,817,573 shares.
Market read
Traders may note mild sentiment support from insider accumulation, but there is no new fundamental catalyst in the filing.
What to watch
The purchase is indirect and there is no 10b5-1 plan disclosed; without context on prior buying/selling patterns, the signal strength is uncertain.
Background
The article is an SEC Form 4 insider transaction disclosure for Artiva Biotherapeutics, Inc.
Ticker impact
RA Capital Management, a director and 10% owner, bought 21,654 Artiva Biotherapeutics shares in open-market trades at about $8.96.
Likely limited near-term impact; any effect is sentiment-driven and typically fades unless followed by larger or repeated buying.
The filing is a Form 4 open-market purchase by an insider/10% owner via indirect holdings, with no new guidance, trial, or deal disclosed. The disclosed size ($194k) is modest relative to typical market-moving thresholds.
Market effects
No clear sector read-through; this is company-specific insider buying with no disclosed program or regulatory change.
None indicated.
None indicated.
Counterpoint
Insider purchases can be routine (tax, liquidity planning, or pre-existing arrangements) and may not reflect a change in business outlook.
Key entities
- issuerArtiva Biotherapeutics, Inc.
Subject of the Form 4 insider transaction disclosure (ARTV).
- insider_filerRA Capital Management, L.P.
Director and 10% owner who reported an indirect open-market purchase.
